Core Viewpoint - WuXi AppTec (02268.HK) has been selected as one of the "Top Ten Core Assets" in the 2026 "Betting on China" list, representing the traditional Chinese medicine industry [2] Group 1: Company Overview - WuXi AppTec was established in 2021 as a joint venture between WuXi Biologics and WuXi AppTec, providing ADC CDMO services and officially listed on the Hong Kong Stock Exchange in November 2023 [3] - The company has become the second-largest ADC CDMO supplier globally, with market share increasing from 1.8% in 2020 to 22% in the first half of 2025 [3][39] Group 2: Industry Background - The rapid development of China's innovative pharmaceutical industry is attributed to policy guidance, capital support, and talent backing, transitioning from a "cost + efficiency" advantage to a technology-leading advantage [9] - The global ADC market is expected to grow significantly, with projections indicating a market size of $13.5 billion in 2024 and $150.2 billion by 2033, with ADC's share of the overall oncology market rising from 5.2% to 27.3% during the same period [18] Group 3: Business Performance - WuXi AppTec's revenue for the first half of 2025 increased by 62.2% to 2.7 billion yuan, with net profit rising by 52.74% to 746 million yuan [27] - The company has executed a total of 858 discovery projects since its inception, with 225 ongoing projects, including 103 in clinical and commercialization stages [30][31] - The company holds a 30% to 35% market share in clinical pipelines globally and has partnerships with 13 of the top 20 pharmaceutical companies [32] Group 4: Future Outlook - The company is expected to continue expanding its production capacity in Wuxi and Singapore, with capital expenditures exceeding 1.5 billion yuan in 2024 and 2025, aiming to double its production capacity by 2029 [39] - Revenue projections for WuXi AppTec are expected to reach 5.97 billion yuan in 2025, 8.06 billion yuan in 2026, and 10.42 billion yuan in 2027, with corresponding growth rates of 47.2%, 35.08%, and 29.35% [40][45] Group 5: Investment Thesis - Investing in WuXi AppTec is essentially a bet on the enhancement of global competitiveness of Chinese innovative drugs and the supporting CXO industry chain [52]

Core Insights - The Huabao CSI Hong Kong Stock Connect Medical Theme ETF (159137) closed with a gain of 0.38% on January 12, with a trading volume of 173 million yuan [1] Fund Overview - The fund was established on December 31, 2025, and is officially named Huabao CSI Hong Kong Stock Connect Medical Theme Exchange-Traded Fund [1] - The management fee is set at 0.50% per annum, while the custody fee is 0.10% per annum [1] - The performance benchmark for the fund is the return of the CSI Hong Kong Stock Connect Medical Theme Index, adjusted for the RMB exchange rate [1] Fund Management - The current fund manager is Zhang Fang, who has managed the fund since its inception, achieving a return of 4.33% during the management period [1] Top Holdings - The latest report indicates that the top holdings of the ETF include: - WuXi Biologics: 2.65% holding, valued at approximately 7.49 million yuan [2] - JD Health: 2.02% holding, valued at approximately 5.71 million yuan [2] - WuXi AppTec: 1.44% holding, valued at approximately 4.07 million yuan [2] - Crystal Digital Holdings: 0.98% holding, valued at approximately 2.76 million yuan [2] - Alibaba Health: 0.93% holding, valued at approximately 2.63 million yuan [2] - WuXi AppTec Holdings: 0.86% holding, valued at approximately 2.43 million yuan [2] - Sinopharm: 0.72% holding, valued at approximately 2.04 million yuan [2] - Genscript Biotech: 0.55% holding, valued at approximately 1.55 million yuan [2] - Ping An Good Doctor: 0.46% holding, valued at approximately 1.31 million yuan [2] - CSPC Pharmaceutical Group: 0.41% holding, valued at approximately 1.17 million yuan [2]

Group 1 - The core viewpoint of the news highlights the performance and growth of the Tianhong Innovation Drug ETF (517380), which has seen significant trading activity and net inflows, indicating strong investor interest in the innovative pharmaceutical sector [1] - As of January 8, the Tianhong Innovation Drug ETF reached a new high with a total scale of 1.597 billion yuan and 1.980 billion shares outstanding, reflecting robust market demand [1] - The ETF tracks the Hang Seng Shanghai-Shenzhen Hong Kong Innovation Drug Select 50 Index (HSSSHID), which includes a diverse selection of 50 leading innovative pharmaceutical companies, with a composition of 40% Hong Kong stocks and 60% A-shares [1] Group 2 - Notable achievements in the innovative pharmaceutical sector include Shiyao Group's R&D expenses of 4.185 billion yuan for the first three quarters of 2025, focusing on ADC, GLP-1, and small nucleic acid pipelines, with total authorized amounts exceeding 9.7 billion USD [2] - BeiGene is projected to achieve a profit of 200 million USD in 2025, with expectations of reaching 600-800 million USD in 2026, as several solid tumor drugs enter critical clinical stages [2] - Three Life Sciences has partnered with Pfizer for a 6 billion USD dual antibody licensing deal, receiving an upfront payment of 1.4 billion USD, with 20 clinical studies planned for 2026 [2]

Core Viewpoint - The article emphasizes the strong performance of the "Betting on China" top ten core asset portfolio, which has significantly outperformed major indices, showcasing the effectiveness of the research institute's asset selection strategy [2][3]. Performance Summary - As of January 5, 2026, the "Betting on China" portfolio increased by 3.6%, outperforming the Shanghai Composite Index's 1.4% and the Hang Seng Index's 2.8% [3]. - Year-to-date, the portfolio has risen by 6.14%, surpassing the Shanghai Composite Index's 2.89% and the Hang Seng Index's 4.29% [3][4]. - Notable individual performances include Alibaba (+7.0%), China Ping An (+5.8%), and WuXi AppTec (+4.4%) from January 2 to 5, 2026 [3][4]. Asset Selection - The core assets selected include: - Zhongji Xuchuang (AI computing/advanced manufacturing) with a market cap of 6,778 million RMB - Tencent (AI applications) with a market cap of 49,160 million RMB - Alibaba (AI/cloud computing) with a market cap of 24,500 million RMB - China Ping An (finance) with a market cap of 12,400 million RMB - WuXi AppTec (pharmaceuticals) with a market cap of 15,151 million RMB [2]. Future Outlook - The strong performance at the beginning of the year is seen as just the start of the value release of the core assets, with the research institute committed to identifying quality targets in China's economic transformation [6].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: WuXi XDC Cayman Inc. 藥明合聯生物技術有限公司*（「本公司」） *僅供識別 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02268 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | 0.00005 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | 0.00005 | ...

Core Insights - The 2026 "Bet on China" top ten core assets have been announced by Gelonghui, a well-known independent research institution in China, based on votes from millions of members across over 70 countries [1][3] - The selection process involved over half a month of voting, resulting in hundreds of thousands of valid votes, emphasizing the collective wisdom of global investors [3] Selection Criteria - The selected listed companies must meet four key principles, reflecting the uncertainties in the Chinese investment market for 2025, including fluctuating recovery expectations, real estate stability concerns, and the ambiguity in investment directions related to AI and new energy [2] Performance Metrics - Since the end of 2018, the "Bet on China" top ten core assets index has achieved a cumulative increase of 318.67%, significantly outperforming the CSI 300 index (+56.2%), Hang Seng index (-0.82%), and S&P 500 index (+175.3%) [3] - In 2025, the equal-weighted return of the top ten core assets reached 35.1%, again surpassing the CSI 300 index (+17.7%), Hang Seng index (+27.8%), and S&P 500 index (+17.3%) [3] Core Assets Overview 1. **Zhongji Xuchuang (300308)**: Expected to benefit from the acceleration of AI computing infrastructure in China, with a projected demand for optical modules reaching 18 billion yuan, and a 50% annual growth in domestic demand for 800G optical modules [5] 2. **Tencent Holdings (00700.HK)**: With a massive user base, Tencent is expected to see its advertising revenue exceed 40 billion yuan in 2026, driven by its social media platforms and AI efficiency improvements [6][7] 3. **Alibaba (09988.HK)**: Anticipated to achieve 170 billion yuan in revenue from cloud services, with a growth rate of 34%, while also focusing on domestic consumption upgrades [7][8] 4. **Gold ETF (518880)**: Positioned as a key hedging tool for domestic investors, with a forecasted gold price potentially reaching 5,000 USD per ounce, supported by liquidity and geopolitical factors [8] 5. **Luoyang Molybdenum (603993/03993.HK)**: Expected to produce 660,000 tons of copper and 120,000 tons of cobalt in 2026, benefiting from the growth of the domestic electric vehicle market [9] 6. **Ping An Insurance (601318/02318.HK)**: Projected to see a 20%-25% increase in market value, benefiting from the domestic interest rate cycle and a focus on quality equity assets [10] 7. **Dongfang Caifu (300059)**: Anticipated to see a 22%-28% growth in market value, driven by increased capital market activity and AI-driven wealth management services [11] 8. **Wanhua Chemical (600309)**: Expected to achieve a net profit of 15.5-16.2 billion yuan in 2026, supported by domestic demand for MDI and new materials [12] 9. **WuXi AppTec (02268.HK)**: Positioned as a leader in the ADC field, with over 60% of its pipeline serving domestic clients, reflecting the growth of China's biopharmaceutical industry [13] 10. **Trip.com Group (09961.HK)**: Projected to see a revenue growth of over 25%, benefiting from the recovery of domestic travel and tourism [14] Conclusion - The ten core assets are aligned with China's key sectors such as AI computing, new energy, consumption, finance, and biomedicine, reflecting the country's new productive forces and upgrading of livelihoods [14]

Core Insights - The article presents the "Top 10 Core Assets for 2026" as voted by millions of members from over 70 countries, highlighting the collective wisdom of global investors in navigating market uncertainties [2][5]. Summary by Categories Core Assets - The selected core assets include: - **Zhongji Xuchuang (中际旭创)**: Market cap of 6,778 million RMB, focusing on AI and advanced manufacturing [3] - **Tencent (腾讯)**: Market cap of 49,160 million RMB, centered on AI applications [3] - **Alibaba (阿里巴巴)**: Market cap of 24,500 million RMB, involved in AI and cloud computing [3] - **Gold ETF (黄金ETF)**: Market cap of 1 million RMB, categorized under precious metals [3] - **Luoyang Molybdenum (洛阳钼业)**: Market cap of 4,279 million RMB, with no specific industry listed [3] - **China Ping An (中国平安)**: Market cap of 12,400 million RMB, in the financial sector [3] - **Dongfang Caifu (东方财富)**: Market cap of 3,663 million RMB, with no specific industry listed [3] - **Wanhua Chemical (万华化学)**: Market cap of 2,400 million RMB, in the chemical industry [3] - **WuXi AppTec (药明合联)**: Market cap of 1,515 million RMB, in the pharmaceutical sector [3] - **Trip.com Group (携程集团)**: Market cap of 3,250 million RMB, in consumer discretionary [3] Market Context - The investment landscape in China for 2025 is characterized by uncertainties, including fluctuating recovery expectations, geopolitical tensions, and evolving trends in real estate and AI [4]. - The article emphasizes the importance of collective intelligence in investment decisions, asserting that the aggregated insights from millions can effectively guide investors through market complexities [5][7]. Performance Metrics - From 2019 to 2025, the "Top 10 Core Assets Index" achieved a cumulative growth of 318.67%, significantly outperforming the CSI 300 Index (+56.2%) and the Hang Seng Index (-0.82%) [11]. - In 2025, the equal-weighted return of the top assets reached 35.1%, again surpassing the performance of major indices [11]. Selection Criteria - The selected companies must meet four key principles: 1. Represent Chinese enterprises with a domestic market focus 2. Align with future economic directions and create long-term value 3. Possess competitive advantages or potential in emerging sectors 4. Have a projected market cap growth of 20% or more in 2026 [10] Individual Company Insights - **Zhongji Xuchuang**: Expected to benefit from a surge in AI-related demand, with a projected market cap growth of 25%-30% [12]. - **Tencent**: Anticipated to see a 25%-30% increase in adjusted net profit, driven by its strong domestic user base and advertising revenue [13]. - **Alibaba**: Forecasted to achieve a 25%-28% stock price increase, supported by its dual focus on AI and consumer markets [14]. - **Gold ETF**: Positioned as a key hedging tool, with a projected 28%-32% growth in fund inflows [15]. - **Luoyang Molybdenum**: Expected to maintain its leading position in the battery materials sector, with a projected net profit of 320-350 million RMB [16]. - **China Ping An**: Anticipated to grow its market cap by 20%-25%, benefiting from the domestic financial market's recovery [17]. - **Dongfang Caifu**: Projected to see a 22%-28% increase in market cap, driven by the growth in wealth management services [18]. - **Wanhua Chemical**: Expected to achieve a net profit of 155-162 million RMB, supported by domestic demand [19]. - **WuXi AppTec**: Positioned as a leader in the ADC field, with significant growth driven by domestic innovation [20]. - **Trip.com Group**: Forecasted to grow revenue by over 25%, capitalizing on the recovery of domestic travel [21]. Conclusion - The selected core assets reflect a strategic alignment with China's economic growth and key sectors, including AI, renewable energy, finance, and healthcare, emphasizing their potential for long-term value creation [22].

Core Viewpoint - The MSCI China Healthcare Index has increased by 51.9% from the beginning of 2025 to date, outperforming the MSCI China Index which rose by 24.3% [1] Group 1: Market Performance - The recent pullback in the healthcare sector has seen the MSCI China Healthcare Index decline by 14% since October [1] - The pullback is attributed to the digestion and rebalancing of valuations and expectations, creating a favorable investment window for future opportunities [1] Group 2: Investment Recommendations - The company recommends a cautious investment approach, focusing on undervalued stocks [1] - Specific stocks recommended for purchase include: - 3SBio Inc. (01530) - Genscript Biotech Corporation (02273) - WuXi AppTec Co., Ltd. (02268) - China National Pharmaceutical Group (01177) - All recommended stocks have a "buy" rating [1] Group 3: Future Outlook - The trend of innovative drugs entering international markets is expected to continue into 2026, with a focus on clinical progress and data validation of pipelines that have already gone abroad [1] - The recently enacted "Biosecurity Law" is anticipated to have limited impact on the operational aspects of Chinese CXO companies [1]

Core Viewpoint - The MSCI China Healthcare Index has increased by 51.9% from the beginning of 2025 to date, outperforming the MSCI China Index which rose by 24.3% [1] Group 1: Investment Recommendations - The company recommends a cautious investment approach, focusing on undervalued stocks [1] - Specific stocks recommended for purchase include: - 3SBio Inc. (01530) - Genscript Biotech Corporation (02273) - WuXi AppTec Co., Ltd. (02268) - China National Pharmaceutical Group (01177) - All recommended stocks have a "Buy" rating [1] Group 2: Market Trends - The healthcare sector has recently experienced a pullback, with the MSCI China Healthcare Index declining by 14% since October [1] - The recent pullback is attributed to the digestion and rebalancing of valuations and expectations, creating a better investment window for the future [1] Group 3: Future Outlook - Looking ahead to 2026, the trend of innovative drugs entering international markets is expected to continue [1] - The focus will be on the clinical progress and data validation of pipelines that have already entered international markets [1] Group 4: Policy Impact - The recently signed and effective "Biological Safety Law" is anticipated to have limited practical impact on the operations of Chinese CXO companies [1]

Market Overview - The US CPI annual rate decline has led to a rise in US stocks, boosting risk market sentiment [1] - The Hang Seng Index opened higher and closed up 0.75%, with the Hang Seng China Enterprises Index and Hang Seng Tech Index rising by 0.68% and 1.12% respectively [1][2] Sector Performance - Major technology stocks saw collective gains, with Tencent up 1.49%, Kuaishou up 1.45%, and Meituan up 1.28% [4] - Pharmaceutical stocks were active, with WuXi AppTec and other related stocks rising [2] - Gaming stocks continued to rise, with MGM China leading with a 6.6% increase [2][5] - AI-driven demand boosted optical fiber and cable stocks, with Yangtze Optical Fiber rising 12% [2] - Automotive, wind power, education, photovoltaic, insurance, and Apple-related stocks also experienced gains [2] Notable Stock Movements - Xpeng Motors rose 7.65%, Horizon Robotics up 7.04%, and Li Auto up 3.81% [4][10] - Electronic cigarette stocks saw significant increases, with China Tobacco Hong Kong up 6.68% [5] - Chinese brokerage stocks rose, with China International Capital Corporation up over 4% [7] - Intelligent driving concept stocks surged, with Youjia Innovation up 31.22% [8] Weak Performers - Heavy machinery stocks faced declines, with China National Heavy Duty Truck Group down over 6% [13] - Gold and precious metal stocks were weak, with several companies experiencing declines of over 2% [16] - Oil stocks also fell, with China Petroleum & Chemical Corporation down 1.52% [15] Capital Flows - Southbound funds recorded a net purchase of HKD 3.371 billion, with net selling from Shanghai-Hong Kong Stock Connect and net buying from Shenzhen-Hong Kong Stock Connect [18] Market Outlook - CITIC Securities suggests that after a strong performance in September, Hong Kong stocks are undergoing a mid-term adjustment, with quality assets entering a high-value zone [18]